- Tumors1000+
- Pathology802
- Cancer792
- Pathologic Processes770
- Nervous System Diseases626
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Pathology802
- Cancer792
- Pathologic Processes770
- Nervous System Diseases626
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- PD-L1 positive
- ER positive
- HER2 positive
- EGFR positive
- PD-L1 negative
- PR positive
- EGFR negative
- ALK negative
- ER negative
- PR negative
- KRAS positive
- BRAF positive
- BRCA1 positive
- ALK positive
- CD20 positive
- BRCA2 positive
- p16 positive
- BRAF negative
- ROS1 negative
- MET positive
- MYC positive
- HLA positive
- PIK3CA positive
- HLA-A positive
- ROS1 positive
- BCL2 positive
- HR positive
- PALB2 positive
- RET positive
- p16 negative
- BCL6 positive
- IDH negative
- IDH positive
- TP53 positive
- BRCA positive
- BRCA1 negative
- HLA negative
- MET negative
- NRAS positive
- TP53 negative
- dMMR positive
- ATM positive
- BCR-ABL1 positive
- BRCA2 negative
- CD19 positive
- CD5 positive
- HBsAg positive
- HLA-A negative
- L858R positive
- MSI-H positive
- RET negative
- CCND1 positive
- Ex19del positive
- HPV negative
- KRAS negative
- MSS positive
- PTEN positive
- RAS positive
- RB1 negative
- RB1 positive
- T790M positive
- TTR positive
- anti-dsDNA positive
- ABCA4 positive
- ANA positive
- CFTR positive
- CLDN18.2 positive
- FGFR2 positive
- FLT3 positive
- HbSS positive
- MDM2 positive
- NF1 positive
- NF2 positive
- NTRK negative
- NTRK positive
- RAS negative
- TROP2 negative
- TROP2 positive
- ctDNA positive
- pMMR positive
- APP positive
- C5 positive
- CD23 positive
- CDK12 positive
- EBV positive
- FLT3 negative
- FMR1 positive
- HPV positive
- JAK2 positive
- MGMT negative
- MGMT positive
- MLH1 positive
- MMR positive
- MSH2 positive
- MSH6 positive
- NRAS negative
- PIK3CA negative
- PMS2 positive
- PSEN1 positive
- PSEN2 positive
- PTEN negative
- Philadelphia chromosome positive
- RF positive
- RHO positive
- SMN1 positive
- p53 positive
- t(11;14) positive
- β-thalassemia positive
- 11q negative
- 11q positive
- AKT negative
- ALPL positive
- Aβ1-42 positive
- BARD1 positive
- BRCA negative
- BRIP1 positive
- CD20 negative
- CD30 positive
- CDK4 positive
- CHEK1 positive
- CHEK2 positive
- COL1A1 positive
- COL1A2 positive
- COL7A1 positive
- DLL3 positive
- DMD positive
- EPCAM positive
- ER/PR positive
- FANCL positive
- FOXO1 fusion negative
- FVIII positive
- G719X positive
- GBA positive
- GPC3 positive
- GRN positive
- H3 K27M positive
- HBB positive
- HBV DNA negative
- HEXA positive
- HEXB positive
- HRAS positive
- HRD positive
- HRR negative
- HRRm positive
- HbE positive
- HbSC positive
- HbSβ0-thalassemia positive
- IGHV positive
- IgHV negative
- KIT positive
- L861Q positive
- MMR negative
- MSI-H negative
- MTAP negative
- MYC negative
- PDE6A positive
- PDE6B positive
- PIK3CD positive
- PIK3R1 positive
- PKLR positive
- PTCH1 positive
- Philadelphia chromosome negative
- PiZZ positive
- RAD51 positive
- RAD51C positive
- RAD51D positive
- RAF positive
- S768I positive
- SPINK5 positive
- STK11 positive
- TMB positive
- TTR negative
- ZnT8 positive
- anti-AChR positive
- anti-MuSK positive
- anti-PLA2R positive
- anti-Ro autoantibodies positive
- anti-Ro/SSA positive
- anti-Sm positive
- anti-Smith positive
- dMMR negative
- del(17p) negative
- kappa light chain positive
- lambda light chain positive
- other sickle cell syndrome variants positive
- 11q del negative
- 12 negative
- 12 positive
- 13q del negative
- 13q negative
- 13q positive
- 16p11.2 deletion positive
- 17p negative
- 17p positive
- 17p13 deletion negative
- 19q negative
- 19q positive
- 1p negative
- 1p positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 Prior Chemotherapy Regimen for Metastatic Disease
- 1927nm Fractional Thulium Laser Treatment
- ALK TKI Therapy
- Adjuvant Therapy (except reconstruction)
- Adjuvant or Neoadjuvant Chemotherapy with Metastatic Disease Development within 6 Months
- Alopecia from Prior Treatment
- Anti-HER2 Therapy
- Anti-Seizure Medications (up to 2 types)
- Any Treatment for Pancreatic Cancer
- At least one prior tumor-directed therapy
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
4208 trials
1
2
3
…50